Foley Advises EpiVax in Acquisition by SV Health Investors

Foley & Lardner LLP served as legal advisor to EpiVax Inc., a leading bioanalytical contract research organization specializing in immunogenicity risk assessments for pharmaceutical and biotech companies, in its acquisition by SV Health Investors, a health care and life sciences focused private investment firm.

EpiVax is a pioneer in pre-clinical drug development, serving as a trusted scientific advisor to life sciences clients. Headquartered in Providence, Rhode Island, EpiVax’s predictive analytical software platform and in vitro laboratory services enable life sciences companies to identify safety and efficacy risks early in drug development, reducing timelines and R&D costs. In partnership with SVHI, EpiVax will continue expanding its capabilities and services, including the planned launch of advanced computational tools, cell-based assay applications, and broader analytical consulting services.

Foley’s health care transactions team was led by partner Joe Derrigo with support from senior counsel Sarah Field and associate Miguel Beltran, partner Jordan Bergmann (Tax), partner Nathan Beaver (Regulatory), and senior counsel Kelsey O’Gorman (Executive Compensation & Benefits).